{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.671","value":"2.18"},{"groupId":"OG001","spread":"1.22","value":"3.07"},{"groupId":"OG002","spread":"1.24","value":"4.23"},{"groupId":"OG003","spread":"0.603","value":"6.03"},{"groupId":"OG004","spread":"1.64","value":"7.33"},{"groupId":"OG005","spread":"0.793","value":"6.44"},{"groupId":"OG006","spread":"1.23","value":"5.52"},{"groupId":"OG007","spread":"1.22","value":"6.00"},{"groupId":"OG008","spread":"1.49","value":"5.28"},{"groupId":"OG009","spread":"1.01","value":"5.79"},{"groupId":"OG010","spread":"1.18","value":"6.18"},{"groupId":"OG011","spread":"1.57","value":"5.90"},{"groupId":"OG012","spread":"1.29","value":"5.61"},{"groupId":"OG013","spread":"1.02","value":"5.46"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"48"},{"groupId":"OG007","value":"49"},{"groupId":"OG008","value":"19"},{"groupId":"OG009","value":"17"},{"groupId":"OG010","value":"17"},{"groupId":"OG011","value":"22"},{"groupId":"OG012","value":"58"},{"groupId":"OG013","value":"21"}],"units":"Participants"}],"description":"The serum PK parameters of Terminal elimination half-life for DS-8201a and its analytes was estimated using standard non-compartmental methods.","dispersionType":"Standard Deviation","groups":[{"description":"Participants in Cohort 1 received an intravenous 0.8 mg/kg dose of DS-8201a (FL-DP1).","id":"OG000","title":"Dose Escalation: Cohort 1, 0.8 mg/kg"},{"description":"Participants in Cohort 2 received an intravenous 1.6 mg/kg dose of DS-8201a (FL-DP1).","id":"OG001","title":"Dose Escalation: Cohort 2, 1.6 mg/kg"},{"description":"Participants in Cohort 3 received an intravenous 3.2 mg/kg dose of DS-8201a (FL-DP1).","id":"OG002","title":"Dose Escalation: Cohort 3, 3.2 mg/kg"},{"description":"Participants in Cohort 4 received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG003","title":"Dose Escalation: Cohort 4, 5.4 mg/kg"},{"description":"Participants in Cohort 5 received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG004","title":"Dose Escalation: Cohort 5, 6.4 mg/kg"},{"description":"Participants in Cohort 6 received an intravenous 8.0 mg/kg dose of DS-8201a (FL-DP1).","id":"OG005","title":"Dose Escalation: Cohort 6, 8.0 mg/kg"},{"description":"Participants with HER2-overexpressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG006","title":"Dose Expansion: HER2-positive Breast Cancer, 5.4 mg/kg"},{"description":"Participants with HER2-overexpressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG007","title":"Dose Expansion: HER2-positive Breast Cancer, 6.4 mg/kg"},{"description":"Participants with HER2-low expressing breast cancer received an intravenous 5.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG008","title":"Dose Expansion: HER2-low Expressing Breast Cancer, 5.4 mg/kg"},{"description":"Participants with HER2-low expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG009","title":"Dose Expansion: HER2-low Expressing Breast Cancer, 6.4 mg/kg"},{"description":"Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG010","title":"Dose Expansion: HER2-overexpressing Gastric or GEJ, 5.4 mg/kg"},{"description":"Participants with HER2-overexpressing gastric or gastroesophageal junction (GEJ) adenocarcinoma received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG011","title":"Dose Expansion: HER2-overexpressing Gastric or GEJ, 6.4 mg/kg"},{"description":"Participants with any other HER2-expressing solid tumor other than breast or gastric or any tumor with HER2 mutation received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP1).","id":"OG012","title":"Dose Expansion: HER2-expressing Other Solid Tumors"},{"description":"Japan only: Participants with HER2-expressing breast cancer received an intravenous 6.4 mg/kg dose of DS-8201a (FL-DP2).","id":"OG013","title":"Dose Expansion: HER2-expressing Breast Cancer"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic parameters were assessed in the Pharmacokinetic Analysis Set.","reportingStatus":"POSTED","timeFrame":"Post first dose up to Day 147","title":"Pharmacokinetic Analysis: Terminal Elimination Half-life (t1/2) of Serum DS-8201a Following First Dose","type":"SECONDARY","unitOfMeasure":"days"}